Northeast Bank (NBN)

Blueprint Medicines Stock Forecast

Stock Price Forecast

The 2 analysts that cover Blueprint Medicines stock have a consensus rating of "Buy" and an average price target of $97.5, which forecasts a 0.65% increase in the stock price over the next year. The lowest target is $80 and the highest is $115.

Price Target: $97.5 (+0.65%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$80	$97.5	$115	$115
Change	-17.42%	+0.65%	+18.72%	+18.72%

* Price targets were last updated on Feb 10, 2025.

Analyst Ratings

The average analyst rating for Blueprint Medicines stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	0	0	0	0	0
Buy	1	1	1	1	1
Hold	1	1	1	1	1
Sell	0	0	0	0	0
Strong Sell	0	0	0	0	0
Total	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Damon Delmonte Keefe, Bruyette & Woods	Keefe, Bruyette & Woods	Hold Maintains $102 → $115	Hold	Maintains	$102 → $115	+18.72%	Feb 10, 2025
Damon Delmonte Keefe, Bruyette & Woods	Keefe, Bruyette & Woods	Hold Initiates $102	Hold	Initiates	$102	+5.30%	Nov 21, 2024
Mark Fitzgibbon Piper Sandler	Piper Sandler	Buy Initiates $80	Buy	Initiates	$80	-17.42%	Sep 11, 2024
Alexander Twerdahl Piper Sandler	Piper Sandler	Buy Maintains $52 → $54	Buy	Maintains	$52 → $54	-44.26%	Oct 25, 2023

More Analyst Ratings

Financial Forecast

Revenue This Year

232.49M

Increased by 13.92%

from 204.09M

Revenue Next Year

n/a

from 232.49M

EPS This Year

10.86

Increased by 7.73%

from 10.08

EPS Next Year

n/a

from 10.86

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Jun 30, 2021	Jun 30, 2022	Jun 30, 2023	Jun 30, 2024	Jun 30, 2025	Jun 30, 2026
Revenue	140.52M	110.33M	121.66M	152.68M	204.09M	232.49M
Revenue Growth	90.73%	-21.48%	10.26%	25.51%	33.67%	13.92%
EPS	8.55	5.34	5.96	7.58	10.08	10.86
EPS Growth	237.95%	-37.54%	11.61%	27.18%	32.98%	7.73%
Forward PE	-	-	-	-	-	8.92
No. Analysts	-	-	-	-	-	2

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026
High	241.7M
Avg	232.5M
Low	225.6M

Revenue Growth

Revenue Growth	2026
High	18.4%
Avg	13.9%
Low	10.5%

EPS Forecast

EPS	2026
High	11.29
Avg	10.86
Low	10.54

EPS Growth

EPS Growth	2026
High	12.0%
Avg	7.7%
Low	4.5%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.